Update on current problems in colorectal liver metastasis

Current Problems in Surgery

Volumn 54, Issue 11, 2017, Pages 554-602

  Chakedis, Jeffrey ^a   Squires, Malcolm H ^a   Beal, Eliza W ^a   Hughes, Tasha ^a   Lewis, Heather ^b   Paredes, Anghela ^a   Al Mansour, Mazen ^a   Sun, Steven ^a   Cloyd, Jordan M ^a   Pawlik, Timothy M ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b University of Colorado Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; YTTRIUM 90;

ABDOMINAL PAIN; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL EVALUATION; COLORECTAL LIVER METASTASIS; CONVALESCENCE; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; EXTRAHEPATIC DISEASE; FATIGUE; FATTY LIVER; FEBRILE NEUTROPENIA; FEVER; HAND FOOT SYNDROME; HEPATIC ARTERIAL INFUSION THERAPY; HUMAN; INTRAOPERATIVE PERIOD; IRREVERSIBLE ELECTROPORATION; KIDNEY FAILURE; LAPAROSCOPIC SURGERY; LIVER DISEASE; LIVER FAILURE; LIVER GRAFT; LIVER INJURY; LIVER PERFUSION; LIVER RESECTION; MINIMALLY INVASIVE SURGERY; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PAIN; PATIENT CARE; PERIOPERATIVE PERIOD; PORTAL VEIN OBSTRUCTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIMARY TUMOR; PROCESS OPTIMIZATION; PROGRESSION FREE SURVIVAL; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REPEAT PROCEDURE; SCORING SYSTEM; SELECTIVE INTERNAL RADIOTHERAPY; STEREOTACTIC BODY RADIATION THERAPY; STOMACH PERFORATION; SURGICAL MORTALITY; SURVIVAL RATE; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; TUMOR ABLATION; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; COLORECTAL TUMOR; HEALTH CARE QUALITY; LIVER TUMOR; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY; TRENDS;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; NEOPLASM METASTASIS; PATIENT SELECTION; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; STANDARD OF CARE;

EID: 85034427337     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2017.10.002     Document Type: Article

References (290)

1. Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:22 (2009), 3677–3683.
2. de Jong, M.C., Pulitano, C., Ribero, D., et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250:3 (2009), 440–448.
3. American Cancer Society. Cancer Facts & Figures 2017. 2017, American Cancer Society, Atlanta, Ga.
4. Leonard, G.D., Brenner, B., Kemeny, N.E., Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23:9 (2005), 2038–2048.
5. Mohammad, W.M., Balaa, F.K., Surgical management of colorectal liver metastases. Clin Colon Rectal Surg 22:4 (2009), 225–232.
6. Nathan, H., de Jong, M.C., Pulitano, C., et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J Am Coll Surg 210:5 (2010), 755–764 [764-6].
7. Riihimaki, M., Hemminki, A., Sundquist, J., Hemminki, K., Patterns of metastasis in colon and rectal cancer. Cancer, 15(6), 2016, 29765.
8. Tie, J., Lipton, L., Desai, J., et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17:5 (2011), 1122–1130.
9. Tran, B., Kopetz, S., Tie, J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117:20 (2011), 4623–4632.
10. Ekberg, H., Tranberg, K.G., Andersson, R., et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg 73:9 (1986), 727–731.
11. Mohammad, W.M., Martel, G., Mimeault, R., Fairfull-Smith, R.J., Auer, R.C., Balaa, F.K., Evaluating agreement regarding the resectability of colorectal liver metastases: a national case-based survey of hepatic surgeons. HPB (Oxford) 14:5 (2012), 291–297.
12. Jones, R.P., Hamann, S., Malik, H.Z., Fenwick, S.W., Poston, G.J., Folprecht, G., Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer 50:9 (2014), 1590–1601.
13. Choti, M.A., Sitzmann, J.V., Tiburi, M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:6 (2002), 759–766.
14. Cummings, L.C., Payes, J.D., Cooper, G.S., Survival after hepatic resection in metastatic colorectal cancer: a population-based study. Cancer 109:4 (2007), 718–726.
15. Kavlakoglu, B., Ustun, I., Oksuz, O., Pekcici, R., Ergocen, S., Oral, S., Surgical treatment of liver metastases from colorectal cancer: experience of a single institution. Arch Iran Med 14:2 (2011), 120–125.
16. House, M.G., Ito, H., Gönen, M., et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J Am Coll Surg 210:5 (2010), 744–752 [752-5].
17. Aloia, T.A., Vauthey, J.N., Loyer, E.M., et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:5 (2006), 460–466 [discussion 466-7].
18. van Dam, R.M., Lodewick, T.M., van den Broek, M.A., et al. Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB (Oxford) 16:6 (2014), 550–559.
19. Pulitano, C., Crawford, M., Joseph, D., Aldrighetti, L., Sandroussi, C., Preoperative assessment of postoperative liver function: the importance of residual liver volume. J Surg Oncol 110:4 (2014), 445–450.
20. Adams, R.B., Aloia, T.A., Loyer, E., Pawlik, T.M., Taouli, B., Vauthey, J.N., Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15:2 (2013), 91–103.
21. Allen, P.J., Kemeny, N., Jarnagin, W., DeMatteo, R., Blumgart, L., Fong, Y., Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7:1 (2003), 109–115 [discussion 116-7].
22. Leung, U., Gönen, M., Allen, P.J., et al. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Ann Surg 265:1 (2017), 158–165.
23. Brudvik, K.W., Jones, R.P., Giuliante, F., et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg, 2017, 10.1097/SLA.0000000000002319 [Epub ahead of print].
24. Shindoh, J., Tzeng, C.W., Aloia, T.A., et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol 20:8 (2013), 2493–2500.
25. Kosuge, T., Makuuchi, M., Takayama, T., et al. Preoperative portal embolization increases safety of hepatectomy. Nihon Geka Gakkai Zasshi 92:9 (1991), 1320–1323.
26. Cieslak, K.P., Huisman, F., Bais, T., et al. Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization. Surgery 162:1 (2017), 37–47.
27. Pawlik, T.M., Scoggins, C.R., Zorzi, D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241:5 (2005), 715–722 [discussion 722-4].
28. Sadot, E., Groot Koerkamp, B., Leal, J.N., et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?. Ann Surg 262:3 (2015), 476–485 [discussion 483-5].
29. Brudvik, K.W., Mise, Y., Chung, M.H., et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 23:8 (2016), 2635–2643.
30. Andreou, A., Aloia, T.A., Brouquet, A., et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg 257:6 (2013), 1079–1088.
31. Margonis, G.A., Spolverato, G., Kim, Y., Ejaz, A., Pawlik, T.M., Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort?. J Gastrointest Surg 19:4 (2015), 699–707.
32. Adson, M.A., van Heerden, J.A., Adson, M.H., Wagner, J.S., Ilstrup, D.M., Resection of hepatic metastases from colorectal cancer. Arch Surg 119:6 (1984), 647–651.
33. Brouquet, A., Vauthey, J.N., Contreras, C.M., et al. Improved survival after resection of liver and lung colorectal metastases compared with liver-only metastases: a study of 112 patients with limited lung metastatic disease. J Am Coll Surg 213:1 (2011), 62–69 [discussion 69-71].
34. Mise, Y., Kopetz, S., Mehran, R.J., et al. Is complete liver resection without resection of synchronous lung metastases justified?. Ann Surg Oncol 22:5 (2015), 1585–1592.
35. Leung, U., Gonen, M., Allen, P.J., et al. Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Ann Surg 265:1 (2017), 158–165.
36. Jaeck, D., Nakano, H., Bachellier, P., et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg Oncol 9:5 (2002), 430–438.
37. Adam, R., de Haas, R.J., Wicherts, D.A., et al. Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery?. Ann Surg 253:2 (2011), 349–359.
38. Adam, R., de Gramont, A., Figueras, J., et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41:9 (2015), 729–741.
39. Martin, R., Paty, P., Fong, Y., et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg 197:2 (2003), 233–241 [discussion 241-2].
40. Martin, R.C., Augenstein, V., Reuter, N.P., Scoggins, C.R., McMasters, K.M., Simultaneous versus staged resection for synchronous colorectal cancer liver metastases. J Am Coll Surg 208:5 (2009), 842–850 [discussion 850-2].
41. Falcone, A., Ricci, S., Brunetti, I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25:13 (2007), 1670–1676.
42. Fakih, M.G., Metastatic colorectal cancer: current state and future directions. J Clin Oncol 33:16 (2015), 1809–1824.
43. Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:9617 (2008), 1007–1016.
44. Nordlinger, B., Sorbye, H., Glimelius, B., et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term esults of a randomised, controlled, phase 3 trial. Lancet Oncol 14:12 (2013), 1208–1215.
45. Maughan, T.S., Adams, R.A., Smith, C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377:9783 (2011), 2103–2114.
46. Primrose, J., Falk, S., Finch-Jones, M., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:6 (2014), 601–611.
47. Benson, A.B. 3rd, Bekaii-Saab, T., Chan, E., et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 11:2 (2013), 141–152 [quiz 152].
48. Stein, A., Glockzin, G., Wienke, A., et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer, 12, 2012, 356.
49. Gruenberger, B., Tamandl, D., Schueller, J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26:11 (2008), 1830–1835.
50. Schwarz, R.E., Berlin, J.D., Lenz, H.J., Nordlinger, B., Rubbia-Brandt, L., Choti, M.A., Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 15:2 (2013), 106–115.
51. Vigano, L., Capussotti, L., De Rosa, G., De Saussure, W.O., Mentha, G., Rubbia-Brandt, L., Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 258:5 (2013), 731–740 [discussion 741-2].
52. Vauthey, J.N., Pawlik, T.M., Ribero, D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:13 (2006), 2065–2072.
53. Robinson, S.M., Wilson, C.H., Burt, A.D., Manas, D.M., White, S.A., Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19:13 (2012), 4287–4299.
54. Yamashita, S., Shindoh, J., Mizuno, T., et al. Hepatic atrophy following preoperative chemotherapy predicts hepatic insufficiency after resection of colorectal liver metastases. J Hepatol 67:1 (2017), 56–64.
55. White, M.A., Fong, Y., Singh, G., Chemotherapy-associated hepatotoxicities. Surg Clin North Am 96:2 (2016), 207–217.
56. Welsh, F.K., Tilney, H.S., Tekkis, P.P., John, T.G., Rees, M., Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96:7 (2007), 1037–1042.
57. Kishi, Y., Zorzi, D., Contreras, C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol 17:11 (2010), 2870–2876.
58. Rojas Llimpe, F.L., Di Fabio, F., Ercolani, G., et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. Br J Cancer 111:4 (2014), 667–673.
59. Zech, C.J., Korpraphong, P., Huppertz, A., et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg 101:6 (2014), 613–621.
60. van Kessel, C.S., Buckens, C.F., van den Bosch, M.A., van Leeuwen, M.S., van Hillegersberg, R., Verkooijen, H.M., Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19:9 (2012), 2805–2813.
61. Desai, D.C., Zervos, E.E., Arnold, M.W., Burak, W.E. Jr., Mantil, J., Martin, E.W. Jr., Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 10:1 (2003), 59–64.
62. Moulton, C.A., Gu, C.S., Law, C.H., et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial. J Am Med Assoc 311:18 (2014), 1863–1869.
63. Lake, E.S., Wadhwani, S., Subar, D., et al. The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis. Ann R Coll Surg Engl 96:3 (2014), 211–215.
64. Niekel, M.C., Bipat, S., Stoker, J., Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257:3 (2010), 674–684.
65. Thirunavukarasu, P., Aloia, T.A., Preoperative assessment and optimization of the future liver remnant. Surg Clin North Am 96:2 (2016), 197–205.
66. Abdalla, E.K., Resection of colorectal liver metastases. J Gastrointest Surg 15:3 (2011), 416–419.
67. Abdalla, E.K., Denys, A., Chevalier, P., Nemr, R.A., Vauthey, J.N., Total and segmental liver volume variations: implications for liver surgery. Surgery 135:4 (2004), 404–410.
68. Simpson, A.L., Geller, D.A., Hemming, A.W., et al. Liver planning software accurately predicts postoperative liver volume and measures early regeneration. J Am Coll Surg 219:2 (2014), 199–207.
69. Vauthey, J.N., Chaoui, A., Do, K.A., et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery 127:5 (2000), 512–519.
70. Zorzi, D., Laurent, A., Pawlik, T.M., Lauwers, G.Y., Vauthey, J.N., Abdalla, E.K., Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:3 (2007), 274–286.
71. Sturesson, C., Nilsson, J., Eriksson, S., Spelt, L., Andersson, R., Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) 15:8 (2013), 646–652.
72. Millet, G., Truant, S., Leteurtre, E., et al. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Ann Surg 256:5 (2012), 755–761 [discussion 761-2].
73. Hoekstra, L.T., de Graaf, W., Nibourg, G.A., et al. Physiological and biochemical basis of clinical liver function tests: a review. Ann Surg 257:1 (2013), 27–36.
74. Beppu, T., Nitta, H., Hayashi, H., et al. Effect of branched-chain amino acid supplementation on functional liver regeneration in patients undergoing portal vein embolization and sequential hepatectomy: a randomized controlled trial. J Gastroenterol 50:12 (2015), 1197–1205.
75. Liu, Z., Li, C., Huang, M., Tong, C., et al. Positive regulatory effects of perioperative probiotic treatment on postoperative liver complications after colorectal liver metastases surgery: a double-center and double-blind randomized clinical trial. BMC Gastroenterol, 15, 2015, 34.
76. Peng, P.D., van Vledder, M.G., Tsai, S., et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB (Oxford) 13:7 (2011), 439–446.
77. Lodewick, T.M., van Nijnatten, T.J., van Dam, R.M., et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?. HPB (Oxford) 17:5 (2015), 438–446.
78. Eriksson, S., Nilsson, J.H., Strandberg Holka, P., Eberhard, J., Keussen, I., Sturesson, C., The impact of neoadjuvant chemotherapy on skeletal muscle depletion and preoperative sarcopenia in patients with resectable colorectal liver metastases. HPB (Oxford) 19:4 (2017), 331–337.
79. Ribero, D., Vigano, L., Amisano, M., Capussotti, L., Prognostic factors after resection of colorectal liver metastases: from morphology to biology. Future Oncol 9:1 (2013), 45–57.
80. Sasaki, K., Andreatos, N., Margonis, G.A., et al. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. J Surg Oncol 114:7 (2016), 803–809.
81. Yamashita, S., Brudvik, K.W., Kopetz, S.E., et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg, 2016, 10.1097/SLA.0000000000002087 [Epub ahead of print].
82. Clancy, C., Burke, J.P., Barry, M., Kalady, M.F., Calvin Coffey, J., A meta-analysis to determine the effect of primary tumor resection for stage IV colorectal cancer with unresectable metastases on patient survival. Ann Surg Oncol 21:12 (2014), 3900–3908.
83. Vigano, L., Russolillo, N., Ferrero, A., et al. Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. Ann Surg 260:5 (2014), 878–884 [discussion 884-5].
84. Vigano, L., Capussotti, L., Lapointe, R., et al. Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 21:4 (2014), 1276–1286.
85. Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:3 (1999), 309–318 [discussion 318-21].
86. Nordlinger, B., Guiguet, M., Vaillant, J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77:7 (1996), 1254–1262.
87. Nagashima, I., Takada, T., Matsuda, K., et al. A new scoring system to classify patients with colorectal liver metastases: proposal of criteria to select candidates for hepatic resection. J Hepatobiliary Pancreat Surg 11:2 (2004), 79–83.
88. Iwatsuki, S., Dvorchik, I., Madariaga, J.R., et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 189:3 (1999), 291–299.
89. Roberts, K.J., White, A., Cockbain, A., et al. Performance of prognostic scores in predicting long-term outcome following resection of colorectal liver metastases. Br J Surg 101:7 (2014), 856–866.
90. Poultsides, G.A., Bao, F., Servais, E.L., et al. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. Ann Surg Oncol 19:9 (2012), 2797–2804.
91. Blazer, D.G. 3rd, Kishi, Y., Maru, D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:33 (2008), 5344–5351.
92. Chun, Y.S., Vauthey, J.N., Boonsirikamchai, P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. J Am Med Assoc 302:21 (2009), 2338–2344.
93. Shindoh, J., Loyer, E.M., Kopetz, S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30:36 (2012), 4566–4572.
94. Brouquet, A., Zimmitti, G., Kopetz, S., et al. Multicenter validation study of pathologic response and tumor thickness at the tumor-normal liver interface as independent predictors of disease-free survival after preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 119:15 (2013), 2778–2788.
95. Egger, M.E., Cannon, R.M., Metzger, T.L., et al. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg 216:4 (2013), 845–856 [discussion 856-7].
96. Lau, L.F., Williams, D.S., Lee, S.T., Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. Ann Surg Oncol 21:7 (2014), 2420–2428.
97. van Vledder, M.G., de Jong, M.C., Pawlik, T.M., Schulick, R.D., Diaz, L.A., Choti, M.A., Disappearing colorectal liver metastases after chemotherapy: should we be concerned?. J Gastrointest Surg 14:11 (2010), 1691–1700.
98. Sturesson, C., Nilsson, J., Lindell, G., Andersson, R.G., Keussen, I., Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities. HPB (Oxford) 17:11 (2015), 983–987.
99. Owen, J.W., Fowler, K.J., Doyle, M.B., Saad, N.E., Linehan, D.C., Chapman, W.C., Colorectal liver metastases: disappearing lesions in the era of Eovist hepatobiliary magnetic resonance imaging. HPB (Oxford) 18:3 (2016), 296–303.
100. Bischof, D.A., Clary, B.M., Maithel, S.K., Pawlik, T.M., Surgical management of disappearing colorectal liver metastases. Br J Surg 100:11 (2013), 1414–1420.
101. Auer, R.C., White, R.R., Kemeny, N.E., et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 116:6 (2010), 1502–1509.
102. Benoist, S., Brouquet, A., Penna, C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 24:24 (2006), 3939–3945.
103. Passot, G., Odisio, B.C., Zorzi, D., et al. Eradication of missing liver metastases after fiducial placement. J Gastrointest Surg 20:6 (2016), 1173–1178.
104. Brudvik, K.W., Kopetz, S.E., Li, L., Conrad, C., Aloia, T.A., Vauthey, J.N., Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102:10 (2015), 1175–1183.
105. Mise, Y., Zimmitti, G., Shindoh, J., et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 22:3 (2015), 834–842.
106. Richman, S.D., Seymour, M.T., Chambers, P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27:35 (2009), 5931–5937.
107. Karagkounis, G., Torbenson, M.S., Daniel, H.D., Azad, N.S., Diaz, L.A., Donehower, R.C., et al. Incidence and Prognostic Impact of KRAS and BRAF Mutation in Patients Undergoing Liver Surgery for Colorectal Metastases. Cancer 119:23 (2013), 4137–4144.
108. Schirripa, M., Bergamo, F., Cremolini, C., et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 112:12 (2015), 1921–1928.
109. Goldstein, J., Tran, B., Ensor, J., et al. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25:5 (2014), 1032–1038.
110. Morris, V., Overman, M.J., Jiang, Z.Q., et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13:3 (2014), 164–171.
111. Kaczirek, K., Ciuleanu, T.E., Vrbanec, D., et al. FOLFOX4 plus cetuximab for patients with previously untreated metastatic colorectal cancer according to tumor RAS and BRAF mutation status: updated analysis of the CECOG/CORE 1.2.002 study. Clin Colorectal Cancer 14:2 (2015), 91–98.
112. Yaeger, R., Cercek, A., Chou, J.F., et al. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 120:15 (2014), 2316–2324.
113. Chun, Y.S., Passot, G., Yamashita, S., et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg, 2017, 10.1097/SLA.0000000000002450 [Epub ahead of print].
114. Yamashita, S., Chun, Y.S., Kopetz, S.E., et al. APC and PIK3CA mutational cooperativity predicts pathologic response and survival in patients undergoing resection for colorectal liver metastases. Ann Surg, 2017, 10.1097/SLA.0000000000002245 [Epub ahead of print].
115. Ito, H., Mo, Q., Qin, L.X., et al. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One, 8(12), 2013, e81680.
116. Mostert, B., Jiang, Y., Sieuwerts, A.M., et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue. Int J Cancer 133:1 (2013), 130–141.
117. Lalmahomed, Z.S., Mostert, B., Onstenk, W., et al. Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. Br J Cancer 112:3 (2015), 556–561.
118. Brudvik, K.W., Seeberg, L.T., Hugenschmidt, H., et al. Detection of circulating tumor cells at surgery and at follow-up assessment to predict survival after two-stage liver resection of colorectal liver metastases. Ann Surg Oncol 22:12 (2015), 4029–4037.
119. Gold, J.S., Are, C., Kornprat, P., et al. Increased use of parenchymal-sparing surgery for bilateral liver metastases from colorectal cancer is associated with improved mortality without change in oncologic outcome: trends in treatment over time in 440 patients. Ann Surg 247:1 (2008), 109–117.
120. Memeo, R., de Blasi, V., Adam, R., et al. Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. HPB (Oxford) 18:9 (2016), 781–790.
121. Mise, Y., Aloia, T.A., Brudvik, K.W., Schwarz, L., Vauthey, J.N., Conrad, C., Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg 263:1 (2016), 146–152.
122. Matsumura, M., Mise, Y., Saiura, A., et al. Parenchymal-sparing hepatectomy does not increase intrahepatic recurrence in patients with advanced colorectal liver metastases. Ann Surg Oncol 23:11 (2016), 3718–3726.
123. Moris, D., Ronnekleiv-Kelly, S., Rahnemai-Azar, A.A., et al. Parenchymal-sparing versus anatomic liver resection for colorectal liver metastases: a systematic review. J Gastrointest Surg 21:6 (2017), 1076–1085.
124. Hoch, G., Croise-Laurent, V., Germain, A., Brunaud, L., Bresler, L., Ayav, A., Is intraoperative ultrasound still useful for the detection of colorectal cancer liver metastases?. HPB (Oxford) 17:6 (2015), 514–519.
125. Torzilli, G., Botea, F., Donadon, M., et al. Criteria for the selective use of contrast-enhanced intra-operative ultrasound during surgery for colorectal liver metastases. HPB (Oxford) 16:11 (2014), 994–1001.
126. van der Vorst, J.R., Schaafsma, B.E., Hutteman, M., et al. Near-infrared fluorescence-guided resection of colorectal liver metastases. Cancer 119:18 (2013), 3411–3418.
127. Peloso, A., Franchi, E., Canepa, M.C., et al. Combined use of intraoperative ultrasound and indocyanine green fluorescence imaging to detect liver metastases from colorectal cancer. HPB (Oxford) 15:12 (2013), 928–934.
128. Brouquet, A., Abdalla, E.K., Kopetz, S., et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol 29:8 (2011), 1083–1090.
129. Chua, T.C., Liauw, W., Chu, F., Morris, D.L., Summary outcomes of two-stage resection for advanced colorectal liver metastases. J Surg Oncol 107:2 (2013), 211–216.
130. Tsai, S., Marques, H.P., de Jong, M.C., et al. Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) 12:4 (2010), 262–269.
131. Simoneau, E., Hassanain, M., Shaheen, M., et al. Portal vein embolization and its effect on tumour progression for colorectal cancer liver metastases. Br J Surg 102:10 (2015), 1240–1249.
132. Shindoh, J., Tzeng, C.W., Aloia, T.A., et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg 100:13 (2013), 1777–1783.
133. Ribero, D., Abdalla, E.K., Madoff, D.C., Donadon, M., Loyer, E.M., Vauthey, J.N., Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 94:11 (2007), 1386–1394.
134. Leung, U., Simpson, A.L., Araujo, R.L., et al. Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg 219:4 (2014), 620–630.
135. Shindoh, J., Truty, M.J., Aloia, T.A., et al. Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 216:2 (2013), 201–209.
136. Mise, Y., Aloia, T.A., Conrad, C., Huang, S.Y., Wallace, M.J., Vauthey, J.N., Volume regeneration of segments 2 and 3 after right portal vein embolization in patients undergoing two-stage hepatectomy. J Gastrointest Surg 19:1 (2015), 133–141 [discussion 141].
137. Schnitzbauer, A.A., Lang, S.A., Goessmann, H., et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255:3 (2012), 405–414.
138. Eshmuminov, D., Raptis, D.A., Linecker, M., Wirsching, A., Lesurtel, M., Clavien, P.A., Meta-analysis of associating liver partition with portal vein ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg 103:13 (2016), 1768–1782.
139. Bertens, K.A., Hawel, J., Lung, K., Buac, S., Pineda-Solis, K., Hernandez-Alejandro, R., ALPPS: challenging the concept of unresectability—a systematic review. Int J Surg 13 (2015), 280–287.
140. Schadde, E., Raptis, D.A., Schnitzbauer, A.A., et al. Prediction of mortality after ALPPS stage-1: an analysis of 320 patients from the International ALPPS Registry. Ann Surg 262:5 (2015), 780–785 [discussion 785-6].
141. Ratti, F., Schadde, E., Masetti, M., et al. Strategies to increase the resectability of patients with colorectal liver metastases: a multi-center case-match analysis of ALPPS and conventional two-stage hepatectomy. Ann Surg Oncol 22:6 (2015), 1933–1942.
142. Adam, R., Imai, K., Castro Benitez, C., et al. Outcome after associating liver partition and portal vein ligation for staged hepatectomy and conventional two-stage hepatectomy for colorectal liver metastases. Br J Surg 103:11 (2016), 1521–1529.
143. Faitot, F., Faron, M., Adam, R., et al. Two-stage hepatectomy versus 1-stage resection combined with radiofrequency for bilobar colorectal metastases: a case-matched analysis of surgical and oncological outcomes. Ann Surg 260:5 (2014), 822–827 [discussion 827-8].
144. Pawlik, T.M., Izzo, F., Cohen, D.S., Morris, J.S., Curley, S.A., Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol 10:9 (2003), 1059–1069.
145. de Jong, M.C., van Vledder, M.G., Ribero, D., et al. Therapeutic efficacy of combined intraoperative ablation and resection for colorectal liver metastases: an international, multi-institutional analysis. J Gastrointest Surg 15:2 (2011), 336–344.
146. Buell, J.F., Cherqui, D., Geller, D.A., et al. The international position on laparoscopic liver surgery: the Louisville Statement, 2008. Ann Surg 250:5 (2009), 825–830.
147. Dagher, I., O'Rourke, N., Geller, D.A., et al. Laparoscopic major hepatectomy: an evolution in standard of care. Ann Surg 250:5 (2009), 856–860.
148. Nguyen, K.T., Marsh, J.W., Tsung, A., Steel, J.J., Gamblin, T.C., Geller, D.A., Comparative benefits of laparoscopic vs open hepatic resection: a critical appraisal. Arch Surg 146:3 (2011), 348–356.
149. Beppu, T., Wakabayashi, G., Hasegawa, K., et al. Long-term and perioperative outcomes of laparoscopic versus open liver resection for colorectal liver metastases with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci 22:10 (2015), 711–720.
150. Mbah, N., Agle, S.C., Philips, P., et al. Laparoscopic hepatectomy significantly shortens the time to postoperative chemotherapy in patients undergoing major hepatectomies. Am J Surg 213:6 (2017), 1060–1064.
151. Vigano, L., Laurent, A., Tayar, C., Tomatis, M., Ponti, A., Cherqui, D., The learning curve in laparoscopic liver resection: improved feasibility and reproducibility. Ann Surg 250:5 (2009), 772–782.
152. Guro, H., Cho, J.Y., Han, H.S., Yoon, Y.S., Choi, Y., Periyasamy, M., Current status of laparoscopic liver resection for hepatocellular carcinoma. Clin Mol Hepatol 22:2 (2016), 212–218.
153. Cloyd, J.M., Visser, B.C., Video-assisted thoracoscopic transdiaphragmatic liver resection for hepatocellular carcinoma. Surg Endosc 26:6 (2012), 1772–1776.
154. Kingham, T.P., Correa-Gallego, C., D'Angelica, M.I., et al. Hepatic parenchymal preservation surgery: decreasing morbidity and mortality rates in 4152 resections for malignancy. J Am Coll Surg 220:4 (2015), 471–479.
155. Coolsen, M.M., Wong-Lun-Hing, E.M., van Dam, R.M., et al. A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery after surgery pathways. HPB (Oxford) 15:4 (2013), 245–251.
156. Portier, G., Elias, D., Bouche, O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:31 (2006), 4976–4982.
157. Mitry, E., Fields, A.L., Bleiberg, H., et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 26:30 (2008), 4906–4911.
158. Ychou, M., Hohenberger, W., Thezenas, S., et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 20:12 (2009), 1964–1970.
159. Sullivan, R.D., Norcross, J.W., Watkins, E., Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med, 1964, 270321–270327.
160. Lewis, H.L., Bloomston, M., Hepatic artery infusional chemotherapy. Surg Clin North Am 96:2 (2016), 341–355.
161. Ensminger, W.D., Rosowsky, A., Raso, V., et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2′-deoxyuridine and 5-fluorouracil. Cancer Res 38:11 Pt 1 (1978), 3784–3792.
162. Dizon, D.S., Schwartz, J., Kemeny, N., Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surg Oncol Clin N Am 17:4 (2008), 759–771 [viii].
163. Sigurdson, E.R., Ridge, J.A., Kemeny, N., Daly, J.M., Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5:11 (1987), 1836–1840.
164. Buchwald, H., Grage, T.B., Vassilopoulos, P.P., Rohde, T.D., Varco, R.L., Blackshear, P.J., Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 45:5 (1980), 866–869.
165. Bacchetti, S., Pasqual, E., Crozzolo, E., Pellarin, A., Cagol, P.P., Intra-arterial hepatic chemotherapy for unresectable colorectal liver metastases: a review of medical devices complications in 3172 patients. Med Devices (Auckl), 2009, 231–240.
166. Cheng, J., Hong, D., Zhu, G., Swanstrom, L.L., Hansen, P.D., Laparoscopic placement of hepatic artery infusion pumps: technical considerations and early results. Ann Surg Oncol 11:6 (2004), 589–597.
167. Qadan, M., D'Angelica, M.I., Kemeny, N.E., Cercek, A., Kingham, T.P., Robotic hepatic arterial infusion pump placement. HPB (Oxford) 19:5 (2017), 429–435.
168. Dhir, M., Zenati, M.S., Padussis, J.C., et al. Robotic assisted placement of hepatic artery infusion pump is a safe and feasible approach. J Surg Oncol 114:3 (2016), 342–347.
169. Kemeny, N., Huang, Y., Cohen, A.M., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. New Engl J Med 341:27 (1999), 2039–2048.
170. Kemeny, N.E., Gonen, M., Hepatic arterial infusion after liver resection. New Engl J Med 352:7 (2005), 734–735.
171. Kemeny, M.M., Adak, S., Gray, B., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. J Clin Oncol 20:6 (2002), 1499–1505.
172. Kemeny, N., Jarnagin, W., Gonen, M., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol 21:17 (2003), 3303–3309.
173. Kemeny, N., Capanu, M., D'Angelica, M., et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 20:7 (2009), 1236–1241.
174. Kemeny, N.E., Chou, J.F., Boucher, T.M., et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol 113:5 (2016), 477–484.
175. House, M.G., Kemeny, N.E., Gonen, M., et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg 254:6 (2011), 851–856.
176. Goere, D., Benhaim, L., Bonnet, S., et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg 257:1 (2013), 114–120.
177. Wurster, E.F., Tenckhoff, S., Probst, P., et al. A systematic review and meta-analysis of the utility of repeated versus single hepatic resection for colorectal cancer liver metastases. HPB (Oxford) 19:6 (2017), 491–497.
178. Passot, G., Soubrane, O., Giuliante, F., et al. Recent advances in chemotherapy and surgery for colorectal liver metastases. Liver Cancer 6:1 (2016), 72–79.
179. Van Cutsem, E., Köhne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
180. Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:10 (2008), 1626–1634.
181. Folprecht, G., Gruenberger, T., Bechstein, W.O., et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11:1 (2010), 38–47.
182. Ye, L.C., Liu, T.S., Ren, L., et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31:16 (2013), 1931–1938.
183. Wong, R., Cunningham, D., Barbachano, Y., et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 22:9 (2011), 2042–2048.
184. Schwartzberg, L.S., Rivera, F., Karthaus, M., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 32:21 (2014), 2240–2247.
185. Cirocchi, R., Trastulli, S., Boselli, C., et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev, 6, 2012, CD006317.
186. Han, Y., Yan, D., Xu, F., Li, X., Cai, J.Q., Radiofrequency ablation versus liver resection for colorectal cancer liver metastasis: an updated systematic review and meta-analysis. Chin Med J (Engl) 129:24 (2016), 2983–2990.
187. Ruers, T., Van Coevorden, F., Punt, C.J., et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst, 109(9), 2017.
188. Ierardi, A.M., Floridi, C., Fontana, F., et al. Microwave ablation of liver metastases to overcome the limitations of radiofrequency ablation. Radiol Med 118:6 (2013), 949–961.
189. Stättner, S., Primavesi, F., Yip, V.S., et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. Surg Today 45:4 (2015), 407–415.
190. Song, C.W., Lee, Y.J., Griffin, R.J., et al. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys 93:1 (2015), 166–172.
191. Méndez Romero, A., de Man, R.A., Stereotactic body radiation therapy for primary and metastatic liver tumors: from technological evolution to improved patient care. Best Pract Res Clin Gastroenterol 30:4 (2016), 603–616.
192. Dawood, O., Mahadevan, A., Goodman, K.A., Stereotactic body radiation therapy for liver metastases. Eur J Cancer 45:17 (2009), 2947–2959.
193. Rusthoven, K.E., Kavanagh, B.D., Cardenes, H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:10 (2009), 1572–1578.
194. Rule, W., Timmerman, R., Tong, L., et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol 18:4 (2011), 1081–1087.
195. Scorsetti, M., Comito, T., Tozzi, A., et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 141:3 (2015), 543–553.
196. Hoyer, M., Roed, H., Traberg Hansen, A., et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol 45:7 (2006), 823–830.
197. Vautravers-Dewas, C., Dewas, S., Bonodeau, F., et al. Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship?. Int J Radiat Oncol Biol Phys 81:3 (2011), e39–e47.
198. Goodman, B.D., Mannina, E.M., Althouse, S.K., Maluccio, M.A., Cárdenes, H.R., Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol 6:2 (2016), 86–95.
199. Lee, M.T., Kim, J.J., Dinniwell, R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 27:10 (2009), 1585–1591.
200. Méndez Romero, A., Wunderink, W., Hussain, S.M., et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase I-II study. Acta Oncol 45:7 (2006), 831–837.
201. Colbert, L.E., Cloyd, J.M., Koay, E.J., Crane, C.H., Vauthey, J.N., Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second-stage hepatectomy. Surgery 161:6 (2017), 1543–1548.
202. Bozkurt, M.F., Salanci, B.V., Uğur, Ö., Intra-arterial radionuclide therapies for liver tumors. Semin Nucl Med 46:4 (2016), 324–339.
203. Kennedy, A.S., Nutting, C., Coldwell, D., Gaiser, J., Drachenberg, C., Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60:5 (2004), 1552–1563.
204. Gulec, S.A., Pennington, K., Wheeler, J., et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol 36:5 (2013), 455–460.
205. Van Hazel, G., Blackwell, A., Anderson, J., et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:2 (2004), 78–85.
206. Hendlisz, A., Van den Eynde, M., Peeters, M., et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28:23 (2010), 3687–3694.
207. Gray, B., Van Hazel, G., Hope, M., et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12:12 (2001), 1711–1720.
208. Cohen, S.J., Konski, A.A., Putnam, S., et al. Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer. Br J Cancer 111:2 (2014), 265–271.
209. van Hazel, G.A., Heinemann, V., Sharma, N.K., et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 34:15 (2016), 1723–1731.
210. Virdee, P.S., Moschandreas, J., Gebski, V., et al. Protocol for combined analysis of FOXFIRE, SIRFLOX, and FOXFIRE-global randomized phase III trials of chemotherapy ± selective internal radiation therapy as first-line treatment for patients with metastatic colorectal cancer. JMIR Res Protoc, 6(3), 2017, e43.
211. Wright, G.P., Marsh, J.W., Varma, M.K., Doherty, M.G., Bartlett, D.L., Chung, M.H., Liver resection after selective internal radiation therapy with yttrium-90 is safe and feasible: a bi-institutional analysis. Ann Surg Oncol 24:4 (2017), 906–913.
212. Wu, P.C., McCart, A., Hewitt, S.M., et al. Isolated organ perfusion does not result in systemic microembolization of tumor cells. Ann Surg Oncol 6:7 (1999), 658–663.
213. Boone, B.A., Bartlett, D.L., Zureikat, A.H., Isolated hepatic perfusion for the treatment of liver metastases. Curr Probl Cancer 36:2 (2012), 27–76.
214. de Leede, E.M., Burgmans, M.C., Martini, C.H., et al. Percutaneous hepatic perfusion (PHP) with melphalan as a treatment for unresectable metastases confined to the liver. J Vis Exp(113), 2016.
215. Bartlett, D.L., Libutti, S.K., Figg, W.D., Fraker, D.L., Alexander, H.R., Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129:2 (2001), 176–187.
216. Alexander, H.R., Libutti, S.K., Bartlett, D.L., et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer 95:4 (2002), 730–736.
217. Alexander, H.R., Libutti, S.K., Pingpank, J.F., Bartlett, D.L., Helsabeck, C., Beresneva, T., Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol 12:2 (2005), 138–144.
218. Alexander, H.R., Bartlett, D.L., Libutti, S.K., Fraker, D.L., Moser, T., Rosenberg, S.A., Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16:4 (1998), 1479–1489.
219. Magge, D., Zureikat, A.H., Bartlett, D.L., et al. A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer. Ann Surg Oncol 20:7 (2013), 2180–2187.
220. Zeh, H.J., Brown, C.K., Holtzman, M.P., et al. A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol 16:2 (2009), 385–394.
221. Schoellhammer, H.F., Goldner, B., Merchant, S.J., Kessler, J., Fong, Y., Gagandeep, S., Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins—a case report. BMC Cancer, 15, 2015, 271.
222. Scheffer, H.J., Vroomen, L.G., Nielsen, K., et al. Colorectal liver metastatic disease: efficacy of irreversible electroporation—a single-arm phase II clinical trial (COLDFIRE-2 trial). BMC Cancer, 15, 2015, 772.
223. Kingham, T.P., Karkar, A.M., D'Angelica, M.I., et al. Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 215:3 (2012), 379–387.
224. Scheffer, H.J., Nielsen, K., van Tilborg, A.A., et al. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol 24:10 (2014), 2467–2475.
225. Cannon, R., Ellis, S., Hayes, D., Narayanan, G., Martin, R.C., Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 107:5 (2013), 544–549.
226. Kasivisvanathan, V., Thapar, A., Oskrochi, Y., Picard, J., Leen, E.L., Irreversible electroporation for focal ablation at the porta hepatis. Cardiovasc Intervent Radiol 35:6 (2012), 1531–1534.
227. Niessen, C., Igl, J., Pregler, B., et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol 26:5 (2015), 694–702.
228. Frühling, P., Nilsson, A., Duraj, F., Haglund, U., Norén, A., Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: short to mid-term results. Eur J Surg Oncol 43:4 (2017), 751–757.
229. Young, S., D'Souza, D., Flanagan, S., Golzarian, J., Review of the clinical evidence for the use of DEBIRI in the treatment of colorectal metastatic disease. Cardiovasc Intervent Radiol 40:4 (2017), 496–501.
230. Lencioni, R., Aliberti, C., de Baere, T., et al. Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol 25:3 (2014), 365–369.
231. Fiorentini, G., Aliberti, C., Tilli, M., et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32:4 (2012), 1387–1395.
232. Martin, R.C., Scoggins, C.R., Tomalty, D., et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16:8 (2012), 1531–1538.
233. Martin, R.C., Scoggins, C.R., Schreeder, M., et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 121:20 (2015), 3649–3658.
234. Akinwande, O., Miller, A., Hayes, D., O'Hara, R., Tomalty, D., Martin, R.C., Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res 34:12 (2014), 7239–7245.
235. Fiorentini, G., Aliberti, C., Sarti, D., et al. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol 7:6 (2015), 47–54.
236. Kerr, D.J., McArdle, C.S., Ledermann, J., et al. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet 361:9355 (2003), 368–373.
237. Lorenz, M., Müller, H.H., Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18:2 (2000), 243–254.
238. Kemeny, N., Eid, A., Stockman, J., et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 91:2 (2005), 97–101.
239. Lévi, F.A., Boige, V., Hebbar, M., et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 27:2 (2016), 267–274.
240. Kemeny, N.E., Melendez, F.D., Capanu, M., et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol 27:21 (2009), 3465–3471.
241. Starzl, T.E., The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg 195:5 (2002), 587–610.
242. Moris, D., Tsilimigras, D.I., Chakedis, J., et al. Liver transplantation for unresectable colorectal liver metastases: a systematic review. J Surg Oncol 116:3 (2017), 288–297.
243. Hagness, M., Foss, A., Line, P.D., et al. Liver transplantation for nonresectable liver metastases from colorectal cancer. Ann Surg 257:5 (2013), 800–806.
244. Dueland, S., Hagness, M., Line, P.D., Guren, T.K., Tveit, K.M., Foss, A., Is liver transplantation an option in colorectal cancer patients with nonresectable liver metastases and progression on all lines of standard chemotherapy?. Ann Surg Oncol 22:7 (2015), 2195–2200.
245. Dueland, S., Guren, T.K., Hagness, M., et al. Chemotherapy or liver transplantation for nonresectable liver metastases from colorectal cancer?. Ann Surg 261:5 (2015), 956–960.
246. Line, P.D., Hagness, M., Berstad, A.E., Foss, A., Dueland, S., A novel concept for partial liver transplantation in nonresectable colorectal liver metastases: the RAPID concept. Ann Surg 262:1 (2015), e5–e9.
247. Rees, M., Tekkis, P.P., Welsh, F.K., O'Rourke, T., John, T.G., Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247:1 (2008), 125–135.
248. Kattan, M.W., Gonen, M., Jarnagin, W.R., et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg 247:2 (2008), 282–287.
249. Yamaguchi, T., Mori, T., Takahashi, K., Matsumoto, H., Miyamoto, H., Kato, T., A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology 55:81 (2008), 173–178.
250. Damm, R., Seidensticker, R., Ulrich, G., et al. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system. BMC Cancer, 16, 2016, 509.
251. Hill, C.R., Chagpar, R.B., Callender, G.G., et al. recurrence following hepatectomy for metastatic colorectal cancer: development of a model that predicts patterns of recurrence and survival. Ann Surg Oncol 19:1 (2012), 139–144.
252. Sasaki, K., Morioka, D., Conci, S., et al. The tumor burden score: a new “Metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg, 2016 [Epub ahead of print].
253. Margonis, G.A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M.A., Pawlik, T.M., Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 22:13 (2015), 4158–4165.
254. Kemeny, N.E., Chou, J.F., Capanu, M., et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 120:24 (2014), 3965–3971.
255. Margonis, G.A., Kim, Y., Spolverato, G., et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 150:8 (2015), 722–729.
256. Vauthey, J.N., Zimmitti, G., Kopetz, S.E., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258:4 (2013), 619–626 [discussion 626-7].
257. Chen, K.F., Yen, C.C., Lin, J.K., et al. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is an independent prognostic marker in wild-type KRAS metastatic colorectal cancer after colorectal liver metastasectomy. BMC Cancer, 15, 2015, 301.
258. Teng, H.W., Huang, Y.C., Lin, J.K., et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 106:2 (2012), 123–129.
259. Styczen, H., Nagelmeier, I., Beissbarth, T., et al. HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget 6:17 (2015), 15065–15076.
260. Goos, J.A., Hiemstra, A.C., Coupe, V.M., et al. Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. Br J Cancer 111:4 (2014), 749–755.
261. Isella, C., Mellano, A., Galimi, F., et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 257:6 (2013), 1089–1095.
262. Martinez-Cecilia, D., Cipriani, F., Vishal, S., et al. Laparoscopic versus open liver resection for colorectal metastases in elderly and octogenarian patients: a multicenter propensity score based analysis of short- and long-term outcomes. Ann Surg 265:6 (2017), 1192–1200.
263. Zeng, Y., Tian, M., Laparoscopic versus open hepatectomy for elderly patients with liver metastases from colorectal cancer. J Buon 21:5 (2016), 1146–1152.
264. Untereiner, X., Cagniet, A., Memeo, R., et al. Laparoscopic hepatectomy versus open hepatectomy for colorectal cancer liver metastases: comparative study with propensity score matching. Hepatobiliary Surg Nutr 5:4 (2016), 290–299.
265. Cipriani, F., Rawashdeh, M., Stanton, L., et al. Propensity score-based analysis of outcomes of laparoscopic versus open liver resection for colorectal metastases. Br J Surg 103:11 (2016), 1504–1512.
266. Lewin, J.W., O'Rourke, N.A., Chiow, A.K., et al. Long-term survival in laparoscopic vs open resection for colorectal liver metastases: inverse probability of treatment weighting using propensity scores. HPB (Oxford) 18:2 (2016), 183–191.
267. Allard, M.A., Cunha, A.S., Gayet, B., et al. Early and long-term oncological outcomes after laparoscopic resection for colorectal liver metastases: a propensity score-based analysis. Ann Surg 262:5 (2015), 794–802.
268. Nachmany, I., Pencovich, N., Zohar, N., et al. Laparoscopic versus open liver resection for metastatic colorectal cancer. Eur J Surg Oncol 41:12 (2015), 1615–1620.
269. Langella, S., Russolillo, N., D'Eletto, M., Forchino, F., Lo Tesoriere, R., Ferrero, A., Oncological safety of ultrasound-guided laparoscopic liver resection for colorectal metastases: a case-control study. Updates Surg 67:2 (2015), 147–155.
270. Hasegawa, Y., Nitta, H., Sasaki, A., et al. Long-term outcomes of laparoscopic versus open liver resection for liver metastases from colorectal cancer: a comparative analysis of 168 consecutive cases at a single center. Surgery 157:6 (2015), 1065–1072.
271. Lin, Q., Ye, Q., Zhu, D., Wei, Y., Ren, L., Zheng, P., et al. Comparison of minimally invasive and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases: a propensity score analysis. Int J Colorectal Dis 30:3 (2015), 385–395.
272. de'Angelis, N., Eshkenazy, R., Brunetti, F., et al. Laparoscopic versus open resection for colorectal liver metastases: a single-center study with propensity score analysis. J Laparoendosc Adv Surg Tech A 25:1 (2015), 12–20.
273. Qiu, J., Chen, S., Pankaj, P., Wu, H., Laparoscopic hepatectomy is associated with considerably less morbidity and a long-term survival similar to that of the open procedure in patients with hepatic colorectal metastases. Surg Laparosc Endosc Percutan Tech 24:6 (2014), 517–522.
274. Montalti, R., Berardi, G., Laurent, S., et al. Laparoscopic liver resection compared to open approach in patients with colorectal liver metastases improves further resectability: oncological outcomes of a case-control matched-pairs analysis. Eur J Surg Oncol 40:5 (2014), 536–544.
275. Iwahashi, S., Shimada, M., Utsunomiya, T., et al. Laparoscopic hepatic resection for metastatic liver tumor of colorectal cancer: comparative analysis of short- and long-term results. Surg Endosc 28:1 (2014), 80–84.
276. Inoue, Y., Hayashi, M., Tanaka, R., Komeda, K., Hirokawa, F., Uchiyama, K., Short-term results of laparoscopic versus open liver resection for liver metastasis from colorectal cancer: a comparative study. Am Surg 79:5 (2013), 495–501.
277. Doughtie, C.A., Egger, M.E., Cannon, R.M., Martin, R.C., McMasters, K.M., Scoggins, C.R., Laparoscopic hepatectomy is a safe and effective approach for resecting large colorectal liver metastases. Am Surg 79:6 (2013), 566–571.
278. Qiu, J., Chen, S., Pankaj, P., Wu, H., Laparoscopic hepatectomy for hepatic colorectal metastases—a retrospective comparative cohort analysis and literature review. PLoS One, 8(3), 2013, e60153.
279. Cheung, T.T., Poon, R.T., Yuen, W.K., et al. Long-term survival analysis of pure laparoscopic versus open hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a single-center experience. Ann Surg 257:3 (2013), 506–511.
280. Guerron, A.D., Aliyev, S., Agcaoglu, O., et al. Laparoscopic versus open resection of colorectal liver metastasis. Surg Endosc 27:4 (2013), 1138–1143.
281. Wang, X., Hershman, D.L., Abrams, J.A., et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br J Cancer 97:12 (2007), 1606–1612.
282. Niu, R., Yan, T.D., Zhu, J.C., Black, D., Chu, F., Morris, D.L., Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol 14:7 (2007), 2078–2087.
283. Malik, H.Z., Prasad, K.R., Halazun, K.J., et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg 246:5 (2007), 806–814.
284. Reissfelder, C., Rahbari, N.N., Koch, M., et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol 16:12 (2009), 3279–3288.
285. Robertson, D.J., Stukel, T.A., Gottlieb, D.J., Sutherland, J.M., Fisher, E.S., Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer 115:4 (2009), 752–759.
286. Hwang, M., Jayakrishnan, T.T., Green, D.E., et al. Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease. Eur J Cancer 50:10 (2014), 1747–1757.
287. Aloia, T.A., Fahy, B.N., Fischer, C.P., et al. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford) 11:6 (2009), 510–515.
288. Cosimelli, M., Golfieri, R., Cagol, P.P., et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103:3 (2010), 324–331.
289. Kemeny, N.E., Niedzwiecki, D., Hollis, D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24:9 (2006), 1395–1403.
290. DʼAngelica, M.I., Correa-Gallego, C., Paty, P.B., et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 261:2 (2015), 353–360.